Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion

Details for Australian Patent Application No. 2006308635 (hide)

Owner Forest Laboratories, Inc.

Inventors Bose, Anjana; Jonas, Jeffrey; Tsai, Joyce

Agent Watermark

Pub. Number AU-A-2006308635

PCT Pub. Number WO2007/053796

Priority 60/804,086 06.06.06 US; 60/727,276 14.10.05 US; 60/810,882 02.06.06 US

Filing date 16 October 2006

Wipo publication date 10 May 2007

International Classifications

A61K 31/138 (2006.01) - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine

Event Publications

29 May 2008 PCT application entered the National Phase

  PCT publication WO2007/053796 Priority application(s): WO2007/053796

31 July 2008 Assignment before Grant

  Forest Laboratories, Inc. The application has been assigned to H. Lundbeck A/S

5 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006308648-Antibodies and immunotoxins that target human glycoprotein NMB

2006308628-Material delivery system using decoupling accumulator